216 related articles for article (PubMed ID: 31376137)
1. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
Koschorke A; Faraci S; Giani D; Chiodoni C; Iorio E; Canese R; Colombo MP; Lamolinara A; Iezzi M; Ladomery M; Vernieri C; de Braud F; Di Nicola M; Tagliabue E; Castagnoli L; Pupa SM
Cell Oncol (Dordr); 2019 Dec; 42(6):815-828. PubMed ID: 31376137
[TBL] [Abstract][Full Text] [Related]
2. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
4. Cancer-preventive effect of phenethyl isothiocyanate through tumor microenvironment regulation in a colorectal cancer stem cell xenograft model.
Shin JM; Lim E; Cho YS; Nho CW
Phytomedicine; 2021 Apr; 84():153493. PubMed ID: 33626429
[TBL] [Abstract][Full Text] [Related]
5. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
[TBL] [Abstract][Full Text] [Related]
6. Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells.
Wang D; Upadhyaya B; Liu Y; Knudsen D; Dey M
BMC Cancer; 2014 Aug; 14():591. PubMed ID: 25127663
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
8. Phenethyl isothiocyanate suppresses cancer stem cell properties in vitro and in a xenograft model.
Yun JH; Kim KA; Yoo G; Kim SY; Shin JM; Kim JH; Jung SH; Kim J; Nho CW
Phytomedicine; 2017 Jul; 30():42-49. PubMed ID: 28545668
[TBL] [Abstract][Full Text] [Related]
9. The landscape of d16HER2 splice variant expression across HER2-positive cancers.
Volpi CC; Pietrantonio F; Gloghini A; Fucà G; Giordano S; Corso S; Pruneri G; Antista M; Cremolini C; Fasano E; Saggio S; Faraci S; Di Bartolomeo M; de Braud F; Di Nicola M; Tagliabue E; Pupa SM; Castagnoli L
Sci Rep; 2019 Mar; 9(1):3545. PubMed ID: 30837627
[TBL] [Abstract][Full Text] [Related]
10. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
11. Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells.
Upadhyaya B; Liu Y; Dey M
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818757
[TBL] [Abstract][Full Text] [Related]
12. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
13. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
14. Phenethyl isothiocyanate inhibits colorectal cancer stem cells by suppressing Wnt/β-catenin pathway.
Chen Y; Li Y; Wang XQ; Meng Y; Zhang Q; Zhu JY; Chen JQ; Cao WS; Wang XQ; Xie CF; Li XT; Geng SS; Wu JS; Zhong CY; Han HY
Phytother Res; 2018 Dec; 32(12):2447-2455. PubMed ID: 30159926
[TBL] [Abstract][Full Text] [Related]
15. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
16. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
Wang W; Gao Y; Hai J; Yang J; Duan S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
[TBL] [Abstract][Full Text] [Related]
17. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
19. Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
Kim YJ; Sung D; Oh E; Cho Y; Cho TM; Farrand L; Seo JH; Kim JY
Cancer Lett; 2018 Jan; 412():118-130. PubMed ID: 29080749
[TBL] [Abstract][Full Text] [Related]
20. Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Castagnoli L; Iorio E; Dugo M; Koschorke A; Faraci S; Canese R; Casalini P; Nanni P; Vernieri C; Di Nicola M; Morelli D; Tagliabue E; Pupa SM
J Cell Physiol; 2019 Feb; 234(2):1768-1779. PubMed ID: 30132876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
